The blood compatibility challenge. Part 3: Material associated activation of blood cascades and cells
Source abstract
Abstract
Following protein adsorption/activation which is the first step after the contact of material surfaces and whole blood (part 2), fibrinogen is converted to fibrin and platelets become activated and assembled in the form of a thrombus. This thrombus formation is the key feature that needs to be minimized in the creation of materials with low thrombogenicity. Further aspects of blood compatibility that are important on their own are complement and leukocyte activation which are also important drivers of thrombus formation. Hence this review summarizes the state of knowledge on all of these cascades and cells and their interactions. For each cascade or cell type, the chapter distinguishes statements which are in widespread agreement from statements where there is less of a consensus. STATEMENT OF SIGNIFICANCE: This paper is part 3 of a series of 4 reviews discussing the problem of biomaterial associated thrombogenicity. The objective was to highlight features of broad agreement and provide commentary on those aspects of the problem that were subject to dispute. We hope that future investigators will update these reviews as new scholarship resolves the uncertainties of today.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Blood properties and coagulation · Hemostasis and retained surgical items · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Contact pathway of coagulation and inflammation10.1186/s12959-015-0048-y ↗
2. Endothelium—role in regulation of coagulation and inflammation10.1007/s00281-011-0285-5 ↗
3. Polyphosphate nanoparticles on the platelet surface trigger contact system activation10.1182/blood-2016-08-734988 ↗
4. In vivo roles of factor XII10.1182/blood-2012-07-292094 ↗
5. Blood coagulation on biomaterials requires the combination of distinct activation processes10.1016/j.biomaterials.2009.05.044 ↗
6. Platelet tissue factor: how did it get there and is it important?10.1053/j.seminhematol.2008.03.012 ↗
7. Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation
8. Should we replace the terms intrinsic and extrinsic coagulation pathways with tissue factor pathway?10.1177/1076029616673733 ↗
9. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis10.1161/ATVBAHA.107.141911 ↗
10. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets10.1002/jbm.a.10155 ↗
11. The ability of surface characteristics of materials to trigger leukocyte tissue factor expression10.1016/j.biomaterials.2009.12.016 ↗
12. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis10.1182/blood-2010-01-264051 ↗
13. Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity10.1016/j.thromres.2016.05.017 ↗
14. P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice10.1182/blood-2014-04-571679 ↗
15. PMNs deliver first aid to clot10.1182/blood-2014-09-597757 ↗
16. Polyamine-promoted autoactivation of plasma hyaluronan-binding protein10.1111/j.1538-7836.2009.03641.x ↗
17. A positively charged surface triggers coagulation activation through factor VII activating protease (FSAP)10.1021/acsami.7b14281 ↗
18. Measurement of the rate of thrombin production in human plasma in contact with different materials10.1002/jbm.820260509 ↗
19. Contact activation of blood-plasma coagulation10.1016/j.biomaterials.2008.12.041 ↗
20. New perspectives on the thrombotic complications of haemolysis10.1111/bjh.13183 ↗
21. Red blood cells: the forgotten player in hemostasis and thrombosis10.1111/jth.14360 ↗
22. Clinical and in vitro evidence that subclinical hemolysis contributes to LVAD thrombosis10.1016/j.athoracsur.2017.05.060 ↗
23. Platelet shape change and cytoskeletal reorganization on polyurethaneureas10.1002/jbm.820230109 ↗
24. Platelet-leukocyte interactions in cardiovascular disease and beyond10.1161/ATVBAHA.110.207480 ↗
25. Systems analysis of thrombus formation10.1161/CIRCRESAHA.115.306824 ↗
26. Effect of heparin-PVA hydrogel on platelets in a chronic canine arterio-venous shunt10.1002/jbm.820230404 ↗
27. In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis
28. Measuring and interpreting platelet-leukocyte aggregates
29. Does surface chemistry affect thrombogenicity of surface modified polymers?10.1002/1097-4636(20010615)55:4<447::AID-JBM1036>3.0.CO;2-5 ↗
30. Variations in the ability of adsorbed fibrinogen to mediate platelet adhesion to polystyrene-based materials: a multivariate statistical analysis of antibody binding to the platelet binding sites of fibrinogen10.1002/jbm.a.20024 ↗
31. Residence-time dependent changes in fibrinogen adsorbed to polymeric biomaterials10.1002/(SICI)1097-4636(19990305)44:3<253::AID-JBM3>3.0.CO;2-K ↗
32. Measuring the time-dependent functional activity of adsorbed fibrinogen by atomic force microscopy10.1021/la801227e ↗
33. Transformation and motility of human platelets: details of the shape change and release reaction observed by optical and electron microscopy10.1083/jcb.83.1.126 ↗
34. Nonthrombogenic treatments and strategies
35. In vitro platelet interactions in whole human blood exposed to biomaterial surfaces: insights on blood compatibility10.1002/jbm.820270909 ↗
36. Blood compatibility assessment of polymers used in drug eluting stent coatings10.1116/1.4944586 ↗
37. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction10.1161/hc3801.095588 ↗
38. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption10.1016/S0142-9612(01)00122-3 ↗
39. Test methods for hemocompatibility of biomaterials
40. Platelet-leukocyte interactions in thrombosis10.1016/j.thromres.2011.10.010 ↗
41. Quantification of shear-induced platelet activation: high shear stresses for short exposure time10.1111/aor.12438 ↗
42. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation10.1038/nm.1955 ↗
43. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers10.1073/pnas.0608422104 ↗
44. On the influence of flow conditions and wettability on blood material interactions10.1016/S0142-9612(03)00380-6 ↗
45. Acquired von Willebrand syndrome associated with left ventricular assist device10.1182/blood-2015-10-636480 ↗
46. Microparticles in hemostasis and thrombosis10.1161/CIRCRESAHA.110.233056 ↗
47. Macrovascular and microvascular function after implantation of left ventricular assist devices in end-stage heart failure: Role of microparticles10.1016/j.healun.2015.03.004 ↗
48. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices10.1016/j.healun.2014.01.004 ↗
49. Platelet mediated complement activation
50. Blood platelets activate the classical pathway of human complement10.1111/j.1538-7836.2006.02065.x ↗
51. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets10.1111/j.1538-7836.2008.03034.x ↗
52. Complement activation on platelets: implications for vascular inflammation and thrombosis10.1016/j.molimm.2010.05.009 ↗
53. Adhesion and activation of platelets from subjects with coronary artery disease and apparently healthy individuals on biomaterials10.1002/jbm.b.33366 ↗
54. Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome10.1253/circj.CJ-13-0742 ↗
55. Platelet dysfunction in type 2 diabetes10.2337/diacare.24.8.1476 ↗
56. Ellipsometric in vitro studies on blood plasma and serum adsorption to zirconium10.1002/1097-4636(200111)57:2<285::AID-JBM1169>3.0.CO;2-C ↗
57. Blood protein-polymer adsorption: implications for understanding complement-mediated hemoincompatibility10.1002/jbm.a.33030 ↗
58. In vitro blood reactivity to hydroxylated and non-hydroxylated polymer surfaces10.1016/j.biomaterials.2007.04.041 ↗
59. Complement activation on surfaces carrying amino groups10.1016/j.biomaterials.2007.10.005 ↗
60. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces10.1002/eji.1830191126 ↗
61. Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies10.1016/j.addr.2011.06.012 ↗
62. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface10.1016/j.biomaterials.2004.05.011 ↗
63. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo10.1038/nnano.2016.269 ↗
64. Target pattern recognition by complement proteins of the classical and alternative pathways10.1007/978-1-4419-0901-5_8 ↗
65. The lectin pathway of complement and biocompatibility10.1007/978-3-319-18603-0_5 ↗
66. Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system
67. Immune complement activation is attenuated by surface nanotopography10.2147/IJN.S24578 ↗
68. Complement interactions with blood cells, endothelial cells and microvesicles in thrombotic and inflammatory conditions10.1007/978-3-319-18603-0_2 ↗
69. C1q as a unique player in angiogenesis with therapeutic implication in wound healing10.1073/pnas.1311968111 ↗
70. Harmful molecular mechanisms in sepsis10.1038/nri2402 ↗
71. Complement activation in arterial and venous thrombosis is mediated by plasmin10.1016/j.ebiom.2016.02.011 ↗
72. Cross talk pathways between coagulation and inflammation10.1161/CIRCRESAHA.116.306853 ↗
73. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development10.1182/blood-2016-11-749879 ↗
74. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-κB activation10.1111/j.1538-7836.2006.02046.x ↗
75. Platelet activation leads to activation and propagation of the complement system10.1084/jem.20041497 ↗
76. Hirudin versus heparin for use in whole blood in vitro biocompatibility models10.1002/jbm.a.32034 ↗
77. Complement analysis in the 21st century10.1016/j.molimm.2007.06.150 ↗
78. Using ELISA to evaluate complement activation by reference biomaterials10.1007/BF00120343 ↗
79. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes10.1016/j.biomaterials.2004.01.023 ↗
80. New therapy, new challenges: the effects of long-term continuous flow left ventricular assist device on inflammation10.1016/j.ijcard.2016.04.133 ↗
81. The role of complement in biomaterial-induced inflammation10.1016/j.molimm.2006.06.020 ↗
82. Human plasma kallikrein releases neutrophil elastase during blood coagulation10.1172/JCI111126 ↗
83. Activation of neutrophil granulocytes in an in vitro model of a cardiopulmonary bypass10.1111/j.1525-1594.2005.00162.x ↗
84. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state10.1016/j.thromres.2012.11.028 ↗
85. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents10.1093/eurheartj/ehp120 ↗
86. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium10.1093/eurheartj/ehv419 ↗
87. Complement inhibition reduces material-induced leukocyte activation with PEG modified polystyrene beads (Tentagel) but not polystyrene beads10.1002/jbm.a.30354 ↗
88. Hemocompatibility testing according to ISO 10993-4: discrimination between pyrogen- and device-induced hemostatic activation10.1016/j.msec.2014.05.070 ↗
89. Endotoxin: the uninvited guest10.1016/j.biomaterials.2005.04.063 ↗
90. Leukocyte-derived microparticles in vascular homeostasis10.1161/CIRCRESAHA.110.233403 ↗
91. Neutrophil extracellular traps kill bacteria10.1126/science.1092385 ↗
92. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms10.1161/ATVBAHA.114.304114 ↗
93. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction10.1093/eurheartj/ehv007 ↗
94. Neutrophil extracellular traps and its implications in inflammation: an overview
95. Thrombosis: tangled up in NETs10.1182/blood-2013-10-463646 ↗
96. Neutrophil extracellular trap formation upon exposure of hydrophobic materials to human whole blood causes thrombogenic reactions10.1039/C7BM00458C ↗
97. Bioreactivity of stent material: activation of platelets, coagulation, leukocytes and endothelial cell dysfunction in vitro10.1080/09537104.2016.1252836 ↗
98. Evaluation of clinical biomaterial surface effects on T lymphocyte activation10.1002/jbm.a.32362 ↗
99. Biocompatibility of implants: lymphocyte/macrophage interactions10.1007/s00281-011-0244-1 ↗
100. Extrinsic and intrinsic pathways of apoptosis in aseptic loosening after total hip replacement10.1016/j.biomaterials.2008.04.044 ↗